Sandra E. Poole

Sandra Poole has been a member of the board of directors of Travere Therapeutics, Inc. since 2019. She brings to Travere more than 25 years of biotechnology industry experience in manufacturing strategy, including chemistry, manufacturing and controls (CMC), technical operations, and product development from research through commercialization. Ms. Poole serves as the chief operating officer of Mythic Therapeutics, an early-stage biotechnology company focused on cancer therapies. Before that, she served as the chief operating officer of LogicBio Therapeutics, Inc., a genome editing company, where she was responsible for leading the company’s internal operations, including all technical functions, quality and regulatory, and supported a successful initial public offering. Prior to LogicBio, Ms. Poole held executive roles of increasing responsibility at ImmunoGen, Inc., a company developing antibody-drug conjugates (ADCs) to treat cancer. While at ImmunoGen, she built technical development and CMC capabilities and built a network of contract manufacturing organizations to manufacture ADCs. Before joining ImmunoGen, Ms. Poole spent more than 15 years in global manufacturing and development leadership positions at Genzyme (now Sanofi Genzyme). Ms. Poole currently serves on the board of directors of ViaCyte, a company focused on regenerative medicine technology to address beta cell loss in type 1 diabetes. Ms. Poole holds an M.A.Sc. and a B.A.Sc. in chemical engineering from the University of Waterloo (Canada).